Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma activity

Malignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being—especially for glioblastomas—extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor (TKR) inhibitors and boron neutron capture therapy (BNCT), together...

Popoln opis

Bibliografske podrobnosti

Glavni avtor:	Alamón, Catalina (author)
Drugi avtorji:	Dávila Saralegui, Belén (author), García Melián, María Fernanda (author), Sánchez, Carina (author), Kovacs, Mariángeles (author), Trias, Emiliano (author), Barbeito, Luis (author), Gabay, Martín (author), Zeineh, Nidal (author), Gavish, Moshe (author), Teixidor, Francesc (author), Viñas, Clara (author), Couto, Marcos (author), Cerecetto, Hugo (author)
Format:	article
Jezik:	angleščina
Izdano:	2020
Teme:	Carborane FLT3 Sub-G1 arrest Anti-tumor activity
Online dostop:	https://hdl.handle.net/20.500.12008/31990
Oznake:	Označite Brez oznak, prvi označite!